SeaStar Medical (ICU) had its "sell (e+)" rating reaffirmed by
Weiss Ratings.
SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026
SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
SeaStar Medical to Report Fourth Quarter and Year-End 2025 Financial Results on March 25, 2026
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing